Moderate Versus Aggressive Fluids for Acute Pancreatitis
This study is not yet open for participant recruitment.
Verified January 2013 by University of Southern California
Sponsor:
University of Southern California
Information provided by (Responsible Party):
James Buxbaum, University of Southern California
ClinicalTrials.gov Identifier:
NCT01761539
First received: January 3, 2013
Last updated: NA
Last verified: January 2013
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Fluid resuscitation for pancreatitis is recommended given evidence that hemoconcentration is associated with necrosis. However, there is insufficient evidence to support whether resuscitation should be moderate or aggressive. In this study the investigators aim to compare the clinical outcome associated with these strategies in a clinical randomized fashion to determine the optimal treatment of acute pancreatitis.
| Condition | Intervention |
|---|---|
|
Pancreatitis |
Other: Aggressive Hydration Other: Moderate Hydration |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Moderate Versus Aggressive Fluid Therapy in Patient With Mild to Moderate Acute Pancratitis |
Resource links provided by NLM:
Genetics Home Reference related topics:
hereditary pancreatitis
MedlinePlus related topics:
Pancreatitis
U.S. FDA Resources
Further study details as provided by University of Southern California:
Primary Outcome Measures:
- Clinical Improvement [ Time Frame: 36 hours ] [ Designated as safety issue: No ]Decreased hematocrit, BUN, Cr compared to time zero, decreased epigastric pain, and ability to tolerate PO's.
Secondary Outcome Measures:
- Time to reach clinical improvement [ Time Frame: 36 hours ] [ Designated as safety issue: No ]Time required to reach clinical improvement (as defined in primary outcome measure)
- Requirement for aggressive hydration [ Time Frame: 36 hours ] [ Designated as safety issue: No ]Patients initally in the moderate hydration arm who have an increase in BUN, CR, Hematocrit, or epigastric pain and thus are crossed over to the aggressive hydration arm.
- Systemic Inflammatory Response Syndrome (SIRS) [ Time Frame: 36 hours ] [ Designated as safety issue: No ]SIRS will be defined based on having 2 out of 4 possible criterion. A) heart rate >90, respiratory rate >20, Temperature greater than 100.4 degrees farenheit or less than 96.8 degrees farenheit. White blood count >10 of <4.
- Severe Pancreatitis [ Time Frame: 36 hours ] [ Designated as safety issue: No ]Severe pancreatitis will be defined if 1 of the following is present; pancreatic necrosis (>30%) or abscess, blood pressure <90mmHg, oxygen saturation <90%, Cr >2mg/dl after 12 hours of resuscitation, >10 days hospitalization, or pseudocyst. Pseudocyst is deefined as a peripancreatic fluid collection which does not resorb within 4-8 weeks.
- Fluid Overload [ Time Frame: 36 hours ] [ Designated as safety issue: Yes ]Physical exam findings of pitting edema, ascites, anasacra, pulmonary edema, or dyspnea.
| Estimated Enrollment: | 60 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | January 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Aggressive Hydration
Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
|
Other: Aggressive Hydration
Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
|
|
Active Comparator: Moderate Hydration
Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
|
Other: Moderate Hydration
Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- mild to moderate pancreatitis
Exclusion Criteria:
- severe pancreatitis
- renal insufficiency, Cr >2 mg/dl
- cardiac insufficiency
- respiratory insufficiency, O2 saturation <90% room air
- liver dysfunction, aklbumin <3mg/dL
- pregnancy
- hyponatremia, Na < 135meq/L
- clinical findings of volume overload peripheral edema ascites
- pancreatitis following endoscopic, radiographic, or surgical procedure
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01761539
Contacts
| Contact: James Buxbaum, MD | 323 409 5371 | jbuxbaum@usc.edu |
| Contact: Maria Trujillo | 323 409 0939 | mit@usc.edu |
Locations
| United States, California | |
| Los Angeles County Hospital | Not yet recruiting |
| Los Angeles, California, United States, 90033 | |
| Contact: Maria Trujillo, MD 323-409-5371 mit@usc.edu | |
| Principal Investigator: James Buxbaum, MD | |
Sponsors and Collaborators
University of Southern California
Investigators
| Principal Investigator: | James L Buxbaum, MD | University of Southern California |
More Information
Publications:
| Responsible Party: | James Buxbaum, Director of Endoscopy, Los Angeles County Hospital, University of Southern California |
| ClinicalTrials.gov Identifier: | NCT01761539 History of Changes |
| Other Study ID Numbers: | HS-12-00499 |
| Study First Received: | January 3, 2013 |
| Last Updated: | January 3, 2013 |
| Health Authority: | United States: Data and Safety Monitoring Board |
Keywords provided by University of Southern California:
|
pancreatitis pancreatitis, alcoholic |
Additional relevant MeSH terms:
|
Pancreatitis Pancreatic Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013